August 25, 2017

Share Start-ups License Agreement

Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody


Grid Therapeutics, LLC, an oncology-focused biotechnology company announced the execution of an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer. Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and diagnostics around CFH. Grid is based on the innovative science developed by Edward F. Patz, Jr., MD and his team at Duke University. Grid is currently developing its lead candidate for the treatment of solid tumors and plans to begin clinical trials in cancer patients in early 2019.

Read more here>